Northland Capmk Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy"

Northland Capmk upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) to a strong-buy rating in a research note released on Friday morning, Zacks.com reports.

Several other research firms have also issued reports on TLSI. Northland Securities began coverage on shares of TriSalus Life Sciences in a research report on Friday. They issued an "outperform" rating and a $12.50 price target on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Thursday, June 27th. Finally, Oppenheimer began coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an "outperform" rating and a $10.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $12.50.

TriSalus Life Sciences Stock Down 1.0 %

NASDAQ TLSI traded down $0.04 during midday trading on Friday, hitting $4.07. The company had a trading volume of 8,510 shares, compared to its average volume of 38,954. The stock has a market cap of $119.29 million, a price-to-earnings ratio of -1.63 and a beta of 0.47. The firm has a fifty day simple moving average of $4.70 and a two-hundred day simple moving average of $6.39. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million for the quarter. As a group, equities analysts predict that TriSalus Life Sciences will post -1.53 earnings per share for the current year.

Insider Transactions at TriSalus Life Sciences

In other news, CEO Mary T. Szela purchased 7,520 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $5.20 per share, with a total value of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares of the company's stock, valued at approximately $1,962,386.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 32.80% of the stock is owned by insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in TLSI. Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter valued at about $240,000. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter valued at about $1,184,000. Finally, Duquesne Family Office LLC increased its position in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after acquiring an additional 110,966 shares in the last quarter. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.